<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01743690</url>
  </required_header>
  <id_info>
    <org_study_id>H-4-2011-143</org_study_id>
    <nct_id>NCT01743690</nct_id>
  </id_info>
  <brief_title>The Use of Probiotics in Patients With Symptomatic Oral Lichen Planus</brief_title>
  <official_title>The Use of Probiotics in Patients With Symptomatic Oral Lichen Planus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim is to investigate the effect of probiotic bacteria on symptoms and clinical
      manifestations in patients with oral lichen planus (OLP).

      The hypothesis is that probiotic bacteria can favor an oral environment that reduces the risk
      of symptomatic candidal and bacterial infection in OLP.

      The negative influence of improper oral hygiene on OLP is established and overgrowth of
      Candida is a common problem. Nystatin is the only topical antifungal that does not interact
      with other drugs and to which the majority of the candida species are susceptible.
      Symptomatic treatment with fluocinolone is initiated in patients without candidal infection.
      Probiotic bacteria can affect the microbial homeostasis by reducing the overgrowth of
      pathogens e.g. candida. Different probiotic species have been shown to produce antifungal
      substances and reduce the growth of candida albicans in vitro. The probiotic strain
      Lactobacillus rhamnosus has been found to reduce the salivary count of yeasts among elderly
      in a randomized clinical study.

      The study is planned as a blinded, randomized controlled study with four parallel arms. 120
      OLP patients with symptoms form the mucous membranes are included in the study and will
      receive nystatin or fluocinolone treatment depending on positive or negative diagnosis of
      candidosis. In addition, they will be assigned to either the probiotic (A) or the placebo
      group (B) by randomization. The groups will be encouraged to take three tablets per day
      (morning, noon and evening)for eight weeks. The lozenges containseither two strains of the
      probiotic bacterium L. reuteri (A) or placebo (B). Cytosmears, saliva sample, and saline
      mouth wash will be taken at baseline, after the treatment period and at follow-up visits at
      8, 16, 24 weeks and 1 year. Salivary counts of the probiotic strains, the clinical
      manifestations and symptoms associated to OLP will be recorded.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>recurrence of candida infections</measure>
    <time_frame>after 1 year</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Oral Lichen Planus</condition>
  <condition>Candida Infection</condition>
  <arm_group>
    <arm_group_label>fluocinolone, placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>fluocinolone, placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fluocinolone, probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fluocinolone, Probiotic lactobacilli reuteri</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nystatin, placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nystatin, placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nystatin, probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nystatin, Probiotic lactobacilli reuteri</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Probiotic lactobacilli reuteri</intervention_name>
    <arm_group_label>fluocinolone, probiotic</arm_group_label>
    <arm_group_label>nystatin, probiotic</arm_group_label>
    <other_name>L. reuteri (DSM 17938 og ATCC PTA 5289) two times a day</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nystatin</intervention_name>
    <arm_group_label>Nystatin, placebo</arm_group_label>
    <arm_group_label>nystatin, probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluocinolone</intervention_name>
    <arm_group_label>fluocinolone, placebo</arm_group_label>
    <arm_group_label>fluocinolone, probiotic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic Oral Lichen Planus

        Exclusion Criteria:

          -  Antibiotic treatment within 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mette K Keller, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2012</study_first_submitted>
  <study_first_submitted_qc>December 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2012</study_first_posted>
  <last_update_submitted>December 10, 2015</last_update_submitted>
  <last_update_submitted_qc>December 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Mette Kirstine Keller</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <keyword>Probiotic</keyword>
  <keyword>Candida</keyword>
  <keyword>Oral Lichen Planus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lichen Planus</mesh_term>
    <mesh_term>Lichen Planus, Oral</mesh_term>
    <mesh_term>Candidiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluocinolone Acetonide</mesh_term>
    <mesh_term>Nystatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

